BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Islatravir readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Islatravir\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06891066-965@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Islatravir: Phase 2 readout est. (NCT06891066)
DESCRIPTION:Islatravir\, phase 2\, HIV.\nStudy: A Study of Islatravir (ISL)
  and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults
  With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)\nEstimate
 d primary completion: 10 August 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/islatravir#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06891066
URL:https://assetmemo.bio/drug/islatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07266831-965@assetmemo.bio
DTSTAMP:20261121T005606Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Islatravir: Phase 2/3 readout est. (NCT07266831)
DESCRIPTION:Islatravir\, phase 2/3\, HIV.\nStudy: A Clinical Study of Islat
 ravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Befo
 re (MK-8591B-062)\nEstimated primary completion: 1 February 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/islatravir#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07266831
URL:https://assetmemo.bio/drug/islatravir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
